Danicopan PMS in Korea
← catalyst calendarNCT07457151 · readout in 678 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
27estimated
Sites
4
Country
South Korea
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-10 | actual | When the study began enrolling |
| Primary completion | 2028-06-27 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-27 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Paroxysmal Nocturnal Hemoglobinuria
Primary outcome
what the primary-completion date above is the date OFSafety (adverse events (AEs), serious AEs (SAEs), adverse drug reactions (ADRs), serious ADRs (SADRs), unexpected AEs/ADRs), AESI
measured Patient data will be gathered for up to 24 weeks from the first dose of the study drug.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed